Cargando…

NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma

Forkhead Box M1 (FOXM1) is an oncogenic transcription factor implicated in the pathogenesis of solid and hematologic cancers. In this study, we examined the significance of FOXM1 in NPM-ALK-positive anaplastic large cell lymphoma (NPM-ALK + ALCL), with a focus on how it interacts with NPM-ALK, which...

Descripción completa

Detalles Bibliográficos
Autores principales: Haque, Moinul, Li, Jing, Huang, Yung-Hsing, Almowaled, Meaad, Barger, Carter J., Karpf, Adam R., Wang, Peng, Chen, Will, Turner, Suzanne D., Lai, Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721812/
https://www.ncbi.nlm.nih.gov/pubmed/31390744
http://dx.doi.org/10.3390/cancers11081119
_version_ 1783448426490363904
author Haque, Moinul
Li, Jing
Huang, Yung-Hsing
Almowaled, Meaad
Barger, Carter J.
Karpf, Adam R.
Wang, Peng
Chen, Will
Turner, Suzanne D.
Lai, Raymond
author_facet Haque, Moinul
Li, Jing
Huang, Yung-Hsing
Almowaled, Meaad
Barger, Carter J.
Karpf, Adam R.
Wang, Peng
Chen, Will
Turner, Suzanne D.
Lai, Raymond
author_sort Haque, Moinul
collection PubMed
description Forkhead Box M1 (FOXM1) is an oncogenic transcription factor implicated in the pathogenesis of solid and hematologic cancers. In this study, we examined the significance of FOXM1 in NPM-ALK-positive anaplastic large cell lymphoma (NPM-ALK + ALCL), with a focus on how it interacts with NPM-ALK, which is a key oncogenic driver in these tumors. FOXM1 was expressed in NPM-ALK + ALCL cell lines (5/5), patient samples (21/21), and tumors arising in NPM-ALK transgenic mice (4/4). FOXM1 was localized in the nuclei and confirmed to be transcriptionally active. Inhibition of FOXM1 in two NPM-ALK + ALCL cells using shRNA and pharmalogic agent (thiostrepton) resulted in reductions in cell growth and soft-agar colony formation, which were associated with apoptosis and cell-cycle arrest. FOXM1 is functionally linked to NPM-ALK, as FOXM1 enhanced phosphorylation of the NPM-ALK/STAT3 axis. Conversely, DNA binding and transcriptional activity of FOXM1 was dependent on the expression of NPM-ALK. Further studies showed that this dependency hinges on the binding of FOXM1 to NPM1 that heterodimerizes with NPM-ALK, and the phosphorylation status of NPM-ALK. In conclusion, we identified FOXM1 as an important oncogenic protein in NPM-ALK+ ALCL. Our results exemplified that NPM-ALK exerts oncogenic effects in the nuclei and illustrated a novel role of NPM1 in NPM-ALK pathobiology.
format Online
Article
Text
id pubmed-6721812
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67218122019-09-10 NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma Haque, Moinul Li, Jing Huang, Yung-Hsing Almowaled, Meaad Barger, Carter J. Karpf, Adam R. Wang, Peng Chen, Will Turner, Suzanne D. Lai, Raymond Cancers (Basel) Article Forkhead Box M1 (FOXM1) is an oncogenic transcription factor implicated in the pathogenesis of solid and hematologic cancers. In this study, we examined the significance of FOXM1 in NPM-ALK-positive anaplastic large cell lymphoma (NPM-ALK + ALCL), with a focus on how it interacts with NPM-ALK, which is a key oncogenic driver in these tumors. FOXM1 was expressed in NPM-ALK + ALCL cell lines (5/5), patient samples (21/21), and tumors arising in NPM-ALK transgenic mice (4/4). FOXM1 was localized in the nuclei and confirmed to be transcriptionally active. Inhibition of FOXM1 in two NPM-ALK + ALCL cells using shRNA and pharmalogic agent (thiostrepton) resulted in reductions in cell growth and soft-agar colony formation, which were associated with apoptosis and cell-cycle arrest. FOXM1 is functionally linked to NPM-ALK, as FOXM1 enhanced phosphorylation of the NPM-ALK/STAT3 axis. Conversely, DNA binding and transcriptional activity of FOXM1 was dependent on the expression of NPM-ALK. Further studies showed that this dependency hinges on the binding of FOXM1 to NPM1 that heterodimerizes with NPM-ALK, and the phosphorylation status of NPM-ALK. In conclusion, we identified FOXM1 as an important oncogenic protein in NPM-ALK+ ALCL. Our results exemplified that NPM-ALK exerts oncogenic effects in the nuclei and illustrated a novel role of NPM1 in NPM-ALK pathobiology. MDPI 2019-08-06 /pmc/articles/PMC6721812/ /pubmed/31390744 http://dx.doi.org/10.3390/cancers11081119 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Haque, Moinul
Li, Jing
Huang, Yung-Hsing
Almowaled, Meaad
Barger, Carter J.
Karpf, Adam R.
Wang, Peng
Chen, Will
Turner, Suzanne D.
Lai, Raymond
NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma
title NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma
title_full NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma
title_fullStr NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma
title_full_unstemmed NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma
title_short NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma
title_sort npm-alk is a key regulator of the oncoprotein foxm1 in alk-positive anaplastic large cell lymphoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721812/
https://www.ncbi.nlm.nih.gov/pubmed/31390744
http://dx.doi.org/10.3390/cancers11081119
work_keys_str_mv AT haquemoinul npmalkisakeyregulatoroftheoncoproteinfoxm1inalkpositiveanaplasticlargecelllymphoma
AT lijing npmalkisakeyregulatoroftheoncoproteinfoxm1inalkpositiveanaplasticlargecelllymphoma
AT huangyunghsing npmalkisakeyregulatoroftheoncoproteinfoxm1inalkpositiveanaplasticlargecelllymphoma
AT almowaledmeaad npmalkisakeyregulatoroftheoncoproteinfoxm1inalkpositiveanaplasticlargecelllymphoma
AT bargercarterj npmalkisakeyregulatoroftheoncoproteinfoxm1inalkpositiveanaplasticlargecelllymphoma
AT karpfadamr npmalkisakeyregulatoroftheoncoproteinfoxm1inalkpositiveanaplasticlargecelllymphoma
AT wangpeng npmalkisakeyregulatoroftheoncoproteinfoxm1inalkpositiveanaplasticlargecelllymphoma
AT chenwill npmalkisakeyregulatoroftheoncoproteinfoxm1inalkpositiveanaplasticlargecelllymphoma
AT turnersuzanned npmalkisakeyregulatoroftheoncoproteinfoxm1inalkpositiveanaplasticlargecelllymphoma
AT lairaymond npmalkisakeyregulatoroftheoncoproteinfoxm1inalkpositiveanaplasticlargecelllymphoma